NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.82) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.83) by $0.01. View Constellation Pharmaceuticals' Earnings History.

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Constellation Pharmaceuticals.

8 brokerages have issued twelve-month price targets for Constellation Pharmaceuticals' stock. Their forecasts range from $40.00 to $65.00. On average, they anticipate Constellation Pharmaceuticals' share price to reach $49.14 in the next year. This suggests a possible upside of 30.7% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Media headlines about CNST stock have trended very positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a news sentiment score of 3.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 1,670,000 shares, a decline of 7.7% from the January 15th total of 1,810,000 shares. Based on an average trading volume of 735,300 shares, the short-interest ratio is presently 2.3 days. Approximately 11.9% of the company's shares are sold short. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Evotec (EVTCY), Nektar Therapeutics (NKTR), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Zai Lab (ZLAB), SAGE Therapeutics (SAGE), PTC Therapeutics (PTCT) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Axsome Therapeutics (AXSM), Canopy Growth (CGC), Sorrento Therapeutics (SRNE), AT&T (T), Arrowhead Pharmaceuticals (ARWR), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), Viking Therapeutics (VKTX) and NIO (NIO).

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (6.88%), Regents of The University of California (4.26%), FMR LLC (3.86%), Casdin Capital LLC (2.96%), Point72 Asset Management L.P. (1.22%) and State Street Corp (0.67%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Karen Valentine, Of The University Of C Regents and Patrick Trojer. View Institutional Ownership Trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, Casdin Capital LLC, P.A.W. Capital Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc. and Bank of America Corp DE. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Of The University Of C Regents and Patrick Trojer. View Insider Buying and Selling for Constellation Pharmaceuticals.

CNST stock was bought by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, Point72 Asset Management L.P., FMR LLC, Franklin Resources Inc., Jennison Associates LLC, Candriam Luxembourg S.C.A., Geode Capital Management LLC and Cadian Capital Management LP. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $37.60.

Constellation Pharmaceuticals has a market capitalization of $1.54 billion. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]